ITPRIPL1 结合 CD3ε 阻碍 T 细胞的激活并使瘤免疫逃逸
Shouyan Deng1, Yibo Zhang1, Huanbin Wang2
1Institutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Zhongshan-Xuhui Hospital, Fudan University, Shanghai 200032, China.
研究人员确定ITPRIPL1是一种抑制T细胞激活的新型免疫检查点. 针对ITPRIPL1的抗体显示出对各种固体瘤的癌症免疫疗法的前景.
科学领域:
- 免疫学
- 癌症学
- 分子生物学
背景情况:
- 由于免疫规避机制,癌症免疫疗法的有效性有所不同.
- 识别新目标对于改善抗癌疗法至关重要.
研究的目的:
- 研究ITPRIPL1在瘤微环境中的T细胞抑制作用.
- 评估ITPRIPL1作为癌症治疗的潜在治疗点.
主要方法:
- 研究ITPRIPL1作为T细胞上的CD3ε的配体.
- 评估ITPRIPL1结合对T细胞激活标志物的影响 (流入,ZAP70酸化).
- 在临床前小鼠模型和自然发生的犬类瘤中测试了对ITPRIPL1的中和抗体.
主要成果:
- ITPRIPL1通过与CD3ε结合直接抑制T细胞激活,减少流和ZAP70酸化.
- 在小鼠模型中,抗体介导的ITPRIPL1阻断抑制了瘤生长和增强了T细胞透.
- 狗类ITPRIPL1抗体在自然发生瘤的物狗中显示出治疗效果.
结论:
- ITPRIPL1是T细胞激活的关键抑制剂,特别是在最初的信号发送阶段.
- 针对ITPRIPL1是一个有前途的新策略,用于增强各种瘤类型的癌症免疫治疗.
更多相关视频
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
相关概念视频
Tumor Immunotherapy
Abnormal Proliferation
Inhibition of Cdk Activity
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
The Tumor Microenvironment
